Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mirtazapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Mirtazapine in Major Depressive Disorder With Insomnia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 07, 2023
Lead Product(s) : Mirtazapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mirtazapine
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Dechra Pharmaceuticals Manufacturing
Deal Size : $43.0 million
Deal Type : Divestment
Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction
Details : The company has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $43.0 million
March 16, 2020
Lead Product(s) : Mirtazapine
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Dechra Pharmaceuticals Manufacturing
Deal Size : $43.0 million
Deal Type : Divestment
Lead Product(s) : Mirtazapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Buddhist Tzu Chi General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 10, 2010
Lead Product(s) : Mirtazapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Buddhist Tzu Chi General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable